Series A · Biotech · Stockholm, Sweden · 11–50 employees
AlzeCure Pharma is a Swedish clinical stage biotech company developing innovative drug therapies for Alzheimer's disease and pain conditions. The company operates three research platforms: NeuroRestore, Alzstatin, and Painless, with multiple drug candidates in different phases. Notable achievements include receiving a EUR 2.5 million grant from the European Innovation Council in 2025 for their NeuroRestore ACD856 Phase II trial, and their ACD440 compound has positive Phase 2 results with FDA orphan drug designation. The company is listed on Nasdaq First North Premier Growth Market and has a diversified pipeline targeting significant unmet medical needs.
No open roles listed right now.